The Scylla and Charybdis of Oral Anticoagulant Treatment
View Full Paper
Ask AI
Bookmark
Share
Why the study?
What is the optimal intensity of oral anticoagulation to balance the risks of thromboembolism and hemorrhage in patients with atrial fibrillation or mechanical heart valves?
Key Points
- To review the clinical efficacy of oral coumarin anticoagulants and address the therapeutic challenges of dosage variability and bleeding risk.
- Literature synthesis examining the pharmacological effects of coumarin derivatives such as warfarin in thromboembolism prevention.
- Evaluation of clinical dosing requirements and safety profiles in patients with atrial fibrillation.
- Anticoagulation reduces the risk of stroke by 70% in patients diagnosed with atrial fibrillation.
- Required therapeutic doses of coumarin derivatives vary up to 10-fold among patients and fluctuate within individuals over time.
- Inappropriate dosing causes ineffective clot prevention during underanticoagulation and increases the danger of severe hemorrhage during overanticoagulation.
Structured PICO
What is the optimal intensity of oral anticoagulation to balance the risks of thromboembolism and hemorrhage in patients with atrial fibrillation or mechanical heart valves?
P
Population
Patients with atrial fibrillation or mechanical heart valves requiring oral anticoagulation
I
Intervention
Oral anticoagulant therapy (coumarin derivatives) monitored to specific INR targets
C
Comparator
Aspirin or lower intensity anticoagulation (discussed generally)
O
Outcome
Ischemic stroke and hemorrhagehard clinical
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
This editorial emphasizes the critical need for specialized monitoring of oral anticoagulation to maintain optimal INR ranges, maximizing stroke prevention while minimizing bleeding risks in patients with atrial fibrillation or mechanical heart valves.
Cite This Study
Frits R. Rosendaal (1996) studied this question.
Topics
View Full Paper
Ask AI
Bookmark
Share